FI831749A0 - Raffinerad avgiftad endotoxinprodukt - Google Patents

Raffinerad avgiftad endotoxinprodukt

Info

Publication number
FI831749A0
FI831749A0 FI831749A FI831749A FI831749A0 FI 831749 A0 FI831749 A0 FI 831749A0 FI 831749 A FI831749 A FI 831749A FI 831749 A FI831749 A FI 831749A FI 831749 A0 FI831749 A0 FI 831749A0
Authority
FI
Finland
Prior art keywords
raffinerad
endotoxinprodukt
avgiftad
raffinerad avgiftad
avgiftad endotoxinprodukt
Prior art date
Application number
FI831749A
Other languages
English (en)
Other versions
FI76494C (fi
FI76494B (fi
FI831749L (fi
Inventor
Edgar Ernst Ribi
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FI831749A0 publication Critical patent/FI831749A0/fi
Publication of FI831749L publication Critical patent/FI831749L/fi
Application granted granted Critical
Publication of FI76494B publication Critical patent/FI76494B/fi
Publication of FI76494C publication Critical patent/FI76494C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FI831749A 1982-05-26 1983-05-18 Foerfarande foer framstaellning av renat, detoxifierat endotoxin. FI76494C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/382,404 US4436727A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product
US38240482 1982-05-26

Publications (4)

Publication Number Publication Date
FI831749A0 true FI831749A0 (fi) 1983-05-18
FI831749L FI831749L (fi) 1983-11-27
FI76494B FI76494B (fi) 1988-07-29
FI76494C FI76494C (fi) 1988-11-10

Family

ID=23508804

Family Applications (1)

Application Number Title Priority Date Filing Date
FI831749A FI76494C (fi) 1982-05-26 1983-05-18 Foerfarande foer framstaellning av renat, detoxifierat endotoxin.

Country Status (21)

Country Link
US (1) US4436727A (fi)
JP (2) JPS58216121A (fi)
KR (1) KR870000842B1 (fi)
AT (1) AT386337B (fi)
AU (1) AU556532B2 (fi)
BE (1) BE896822A (fi)
CA (1) CA1185899A (fi)
CH (1) CH661526A5 (fi)
DE (1) DE3318569A1 (fi)
DK (1) DK159275C (fi)
FI (1) FI76494C (fi)
FR (1) FR2527613B1 (fi)
GB (1) GB2122204B (fi)
HU (1) HU190491B (fi)
IL (1) IL68713A (fi)
IN (1) IN156144B (fi)
IT (1) IT1164242B (fi)
NL (1) NL194865C (fi)
NO (1) NO154864C (fi)
NZ (1) NZ204298A (fi)
SE (1) SE462017B (fi)

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPS61151157A (ja) * 1984-12-25 1986-07-09 Seiko Instr & Electronics Ltd タンパク質を加水分解する方法
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
JPH01141942U (fi) * 1988-03-24 1989-09-28
JPH01180041U (fi) * 1988-06-09 1989-12-25
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
ES2019728A6 (es) * 1988-09-23 1991-07-01 Univ Southern California Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
JPH02124341U (fi) * 1989-03-24 1990-10-12
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
JP2002500001A (ja) 1997-09-10 2002-01-08 ヴァイオン ファーマシューティカルズ、インコーポレーテッド 低下した毒性を有する遺伝子改変腫瘍標的化細菌
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100682154B1 (ko) * 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
NZ509974A (en) 1998-08-07 2003-10-31 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6013640A (en) 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP2277892A3 (en) 1998-12-08 2011-04-27 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2000058456A2 (en) * 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EA005140B1 (ru) 1999-04-02 2004-12-30 Корикса Корпорейшн Соединения и способы для лечения и диагностики рака легкого
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
JP2003510370A (ja) * 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
PT1265915E (pt) 2000-02-23 2011-02-07 Glaxosmithkline Biolog Sa Novos compostos
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
CA2407114A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US20030139356A1 (en) 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
BR0110975A (pt) 2000-05-19 2004-03-23 Corixa Corp Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
WO2001098460A2 (en) * 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20030108565A1 (en) 2001-07-10 2003-06-12 Johnson Mark E. Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
EP2322626A1 (en) 2001-09-20 2011-05-18 Glaxo Group Limited HIV-GAG codon-optimised DNA vaccines
CA2860702C (en) 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
NZ537655A (en) 2002-07-08 2006-12-22 Corixa Corp Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
SI2269656T1 (sl) 2002-07-15 2014-11-28 Board Of Regents, The University Of Texas System Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
AU2003252052A1 (en) 2002-07-18 2004-02-09 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
MXPA05007295A (es) 2003-01-06 2005-09-30 Corixa Corp Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso.
PL2272532T3 (pl) 2003-09-02 2016-07-29 Glaxosmithkline Biologicals Sa Szczepionka rotawirusowa
WO2005071058A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
EP1735338B1 (en) * 2004-02-11 2013-04-24 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US8846051B2 (en) 2004-10-08 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by deoptimization of synonymous codons
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
KR20070116652A (ko) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을유도하는 인플루엔자 바이러스 및 수중유 에멀젼애주번트의 용도
EP2392347A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
SI2426141T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Postopek za preprečevanje ali zdravljenje infekcije z M tuberculosis
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
JP5654345B2 (ja) 2007-08-02 2015-01-14 ビオンドヴァックス ファーマシューティカルズ リミテッド 多量体マルチエピトープインフルエンザワクチン
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
DK2224954T3 (en) 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
WO2009073179A2 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
PT2222710T (pt) 2007-12-24 2016-11-02 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
AU2009259964B2 (en) 2008-06-19 2015-04-09 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
JP2011528222A (ja) * 2008-07-18 2011-11-17 アイディー バイオメディカル コーポレイション オブ ケベック キメラ呼吸器合胞体ウイルスポリペプチド抗原
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US20110236470A1 (en) 2008-12-03 2011-09-29 Yaffa Mizrachi Nebenzahl GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
BRPI1014031A2 (pt) 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
EP2445526B1 (en) 2009-06-24 2016-05-11 GlaxoSmithKline Biologicals S.A. Recombinant rsv antigens
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
US20120244185A1 (en) 2009-09-16 2012-09-27 Vaxart ,Inc. Immunization strategy to prevent h1n1 infection
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
KR20130140009A (ko) 2010-10-15 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 사이토메갈로바이러스 ｇｂ 항원
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EA201390676A1 (ru) 2010-11-08 2013-11-29 Инфекшес Дизиз Рисерч Инститьют Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
PT3023106T (pt) 2010-12-14 2019-11-04 Glaxosmithkline Biologicals Sa Composição antigénica de micobactéria
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
PT3275892T (pt) 2011-05-13 2020-04-08 Glaxosmithkline Biologicals Sa Antigénios f de rsv de pré-fusão
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
BR112014006175B1 (pt) 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP4299138A3 (en) 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
PT2928489T (pt) 2012-12-05 2019-05-28 Glaxosmithkline Biologicals Sa Composição imunogénica
EP2941258B1 (en) 2013-01-02 2019-09-11 Decoy Biosystems, Inc. Compositions and methods for treatment of cancer using bacteria
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN112851766A (zh) 2013-03-13 2021-05-28 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
EP2968521A2 (en) 2013-03-15 2016-01-20 GlaxoSmithKline Biologicals S.A. Vaccine
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
EP3492097A1 (en) 2013-08-05 2019-06-05 GlaxoSmithKline Biologicals S.A. Combination immunogenic compositions
EP3046579A1 (en) 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
US10208102B2 (en) 2013-11-01 2019-02-19 University Of Oslo Albumin variants and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA2939581C (en) 2014-02-20 2024-01-23 Vaxart, Inc. Formulations for small intestinal delivery
WO2015151103A1 (en) 2014-04-03 2015-10-08 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
MX374380B (es) 2014-06-25 2025-03-06 Glaxosmithkline Biologicals Sa Composicion inmunógena de clostridium difficile.
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
ES2881346T3 (es) 2014-12-19 2021-11-29 Regenesance B V Anticuerpos que se unen a C6 humano y usos de los mismos
CA2974237C (en) 2015-01-09 2021-07-20 Etubics Corporation Methods and compositions for combination immunotherapy
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
CN107708730A (zh) 2015-05-26 2018-02-16 俄亥俄州创新基金会 针对猪流感病毒的基于纳米粒子的疫苗策略
EA201792512A1 (ru) 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
KR20180114946A (ko) 2016-03-02 2018-10-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 sting 활성화 나노백신
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CN116789830A (zh) 2016-03-14 2023-09-22 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
IL299285B2 (en) 2016-05-16 2024-12-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
MX2018014602A (es) 2016-05-27 2019-06-10 Etubics Corp Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
CA3030779A1 (en) 2016-07-13 2018-01-18 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MX2019006728A (es) 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR102595238B1 (ko) 2017-04-19 2023-10-26 인스티튜트 포 리서치 인 바이오메드슨 말라리아원충 종충에 결합하는 신규한 말라리아 백신 및 항체.
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
DE112018002827T5 (de) 2017-05-30 2020-04-09 Glaxosmithkline Biologicals S.A. Neue Verfahren zur Herstellung eines Adjuvans
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and their uses
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN111836639A (zh) 2018-01-26 2020-10-27 河谷细胞有限公司 用于联合癌症疫苗和免疫辅助疗法的组合物和方法
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
MX2021001129A (es) 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
JP2022542032A (ja) 2019-07-21 2022-09-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療用ウイルスワクチン
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
BR112022004228A2 (pt) 2019-09-09 2022-05-31 Glaxosmithkline Biologicals Sa Composições imunoterapêuticas
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
KR20220128372A (ko) 2020-01-16 2022-09-20 얀센 파마슈티칼즈, 인코포레이티드 Fimh 돌연변이체, 이를 갖는 조성물 및 이의 용도
WO2021178637A1 (en) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
BR112022020660A2 (pt) 2020-05-05 2022-11-29 Glaxosmithkline Biologicals Sa Dispositivo de mistura microfluídica e métodos de uso
WO2021245025A1 (en) 2020-06-01 2021-12-09 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
CA3203278A1 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
CA3202311A1 (en) 2020-12-24 2022-06-30 Anne Osbourn Methods and enzymes for producing quillaic acid derivatives
KR102746713B1 (ko) 2021-01-12 2024-12-24 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
US20240131140A1 (en) 2021-02-11 2024-04-25 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
WO2022217019A1 (en) 2021-04-09 2022-10-13 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250207166A1 (en) 2022-03-25 2025-06-26 Plant Bioscience Limited Biosynthesis
EP4540401A1 (en) 2022-06-15 2025-04-23 GlaxoSmithKline Biologicals S.A. Enzymatic modification of saponins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE185031C (fi) *
DE472221C (de) * 1924-04-01 1929-02-25 Kalle & Co Akt Ges Verfahren zur Gewinnung der toxischen Komponenten aus den Aufschluessen von Bakterien
FR2393065A1 (fr) * 1977-05-31 1978-12-29 Merieux Inst Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis

Also Published As

Publication number Publication date
CA1185899A (en) 1985-04-23
JPH042573B2 (fi) 1992-01-20
IL68713A0 (en) 1983-09-30
JPS6313968B2 (fi) 1988-03-29
FR2527613B1 (fr) 1987-02-27
SE8302774D0 (sv) 1983-05-18
FI76494C (fi) 1988-11-10
DE3318569A1 (de) 1984-01-12
KR870000842B1 (ko) 1987-04-25
DE3318569C2 (fi) 1987-10-29
NO154864B (no) 1986-09-29
IL68713A (en) 1986-02-28
FR2527613A1 (fr) 1983-12-02
NO831855L (no) 1983-11-28
ATA189483A (de) 1988-01-15
NZ204298A (en) 1986-10-08
AU1461483A (en) 1983-12-01
HU190491B (en) 1986-09-29
KR840004510A (ko) 1984-10-22
AU556532B2 (en) 1986-11-06
US4436727A (en) 1984-03-13
IT1164242B (it) 1987-04-08
NL8301842A (nl) 1983-12-16
DK221883D0 (da) 1983-05-18
IN156144B (fi) 1985-05-25
JPS58216121A (ja) 1983-12-15
DK159275B (da) 1990-09-24
BE896822A (fr) 1983-09-16
SE8302774L (sv) 1983-11-27
DK159275C (da) 1991-02-18
FI76494B (fi) 1988-07-29
FI831749L (fi) 1983-11-27
GB8313253D0 (en) 1983-06-22
DK221883A (da) 1983-11-27
SE462017B (sv) 1990-04-30
NL194865C (nl) 2003-05-06
IT8321287A0 (it) 1983-05-25
CH661526A5 (de) 1987-07-31
AT386337B (de) 1988-08-10
NL194865B (nl) 2003-01-06
NO154864C (no) 1987-01-07
GB2122204A (en) 1984-01-11
JPS6345225A (ja) 1988-02-26
GB2122204B (en) 1985-12-24

Similar Documents

Publication Publication Date Title
FI831749L (fi) Raffinerad avgiftad endotoxinprodukt
FI833637A0 (fi) Centralenhet foer databehandlingssystem
FI822307A0 (fi) Volymreglerbar pipett
FI830950A0 (fi) Baerelement
BE895653A (fr) Katalytische verbrander
BR8304069A (pt) Pessario intra-ulterino
NO151564C (no) Kondens-eliminator
FI832580A0 (fi) Digitalt transmissionssystem
FI821670L (fi) Elektrodsystem foer voltametriska maetningar
BR8208084A (pt) Microcomutador
BE895921A (fr) Sterilet
BE894865A (fr) Biertransportwagen
FI831632A0 (fi) Fluidiseringsanordning
DK357382A (da) Hulskaerer
AT373020B (de) Ruestungstraeger
AT381170B (de) Hypsometer
AT382452B (de) Drehrohrofen
BE895597A (fr) Verwarmingsstelsel
AR226015A1 (es) Catre-reposera
AR225385A1 (es) Jeringa-ampolla
ATA92682A (de) Drehrohrofen
BR6200467U (pt) Pantalha
ATA280282A (de) Grasschi
ATA13982A (de) Schistock
BR6200562U (pt) Saleiro

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.